V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220018217 | 220009725 | null | null | Palliative (P) | 2012-02-29 | 2013-07-19 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN | N | N | 220020796 | LENALIDOMIDE |
| 220018219 | 220009729 | 1.7 | 57.1 | Palliative (P) | 2015-01-04 | 2015-01-13 | Busulfan + Cyclophos Conditioning | N | N | 220021070 | ALL INTERIM GUIDELINES |
| 220018220 | 220009731 | 1.67 | 66.95 | Palliative (P) | 2018-01-20 | 2018-01-21 | Sorafenib | N | null | 220021563 | LENALIDOMIDE |
| 220018221 | 220009733 | null | 103 | Palliative (P) | 2017-02-07 | 2017-09-21 | BENDAMUSTINE + RITUXIMAB | N | Y | 220021657 | OSIMERTINIB |
| 220018222 | 220015132 | 1.8 | 67.5 | Palliative (P) | 2014-06-12 | 2014-06-25 | CISPLATIN + RT | N | N | 220021758 | DABRAFENIB |
| 220018223 | 220015133 | null | 65.8 | Palliative (P) | 2016-11-28 | 2017-09-25 | Ipilimumab | N | N | 220021916 | PERTUZUMAB + TRASTUZUMAB |
| 220018224 | 220015133 | 1.8 | 106.2 | Palliative (P) | 2019-04-07 | 2019-06-15 | MA (Cytarabine 3g/m2) | 02 | N | 220021916 | ARSENIC TRIOXIDE + ATRA |
| 220018225 | 220009740 | 1.74 | 66 | Neo-adjuvant (N) | 2015-01-15 | 2015-01-17 | Ipilimumab | 2 | N | 220022309 | PEMBROLIZUMAB |
| 220018226 | 220009742 | null | 70 | Palliative (P) | 2018-11-26 | 2018-11-26 | Bevacizumab+Carbo+Pacliaxel | N | null | 220022614 | NHL 2003 |
| 220018227 | 220021034 | 1.65 | 0 | Neo-adjuvant (N) | 2014-10-15 | 2015-01-06 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE | 02 | N | 220022881 | CARBOPLATIN |
| 220018228 | 220009748 | 1.8 | 102.2 | Palliative (P) | 2015-06-29 | 2015-07-29 | INTERFERON | 02 | Y | 220023457 | INTERFERON |
| 220018229 | 220009750 | null | 97 | Disease modification (D) | 2016-07-11 | 2016-08-09 | Arsenic Triox + Tretinoin Ind W1-4 | N | N | 220023979 | VINORELBINE |
| 220018230 | 220009751 | null | null | Disease modification (D) | 2014-07-02 | 2014-08-09 | MidAC | Y | N | 220024165 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 220018231 | 220009753 | 1.62 | 0 | null | 2014-08-14 | 2014-08-18 | Everolimus 10mg | N | N | 220025845 | CVAD |
| 220018232 | 220009756 | 1.9 | 0 | null | 2018-10-01 | 2018-11-15 | Arsenic Triox + Tretinoin Ind W1-4 | N | N | 220026216 | TRASTUZUMAB |
| 220018233 | 220009758 | 1.49 | 68.7 | Palliative (P) | 2017-08-10 | 2017-08-19 | FIGARO TRIAL | N | N | 220026615 | VINORELBINE |
| 220018234 | 220009759 | 1.63 | 125 | Curative (C) | 2018-03-11 | 2018-11-07 | CYTARABINE + MITOXANTRONE | N | N | 220026657 | VIOLA TRIAL |
| 220018235 | 220018253 | 1.75 | 80.3 | Disease modification (D) | 2018-03-27 | 2018-03-29 | CISPLATIN + FLUOROURACIL | N | N | 220027021 | VENETOCLAX |
| 220018236 | 220015140 | 0 | 79.3 | Curative (C) | 2018-06-10 | 2018-08-12 | CISPLATIN + FLUOROURACIL | N | N | 220027282 | CLADRIBINE |
| 220018237 | 220015141 | null | 100 | null | 2015-12-11 | 2015-12-15 | CETUXIMAB | null | null | 220027517 | UKALL2011 |
| 220018238 | 220009765 | 1.83 | 51 | Curative (C) | 2017-02-11 | 2017-03-06 | GEMCITABINE + OXALIPLATIN + PACLITAXEL | N | null | 220027666 | MYELOMA XI TRIAL |
| 220018239 | 220015142 | 1.75 | 83.3 | Palliative (P) | 2018-07-26 | 2018-07-26 | MERCAPTOPURINE + METHOTREXATE | 01 | N | 220027990 | CYTARABINE + MITOXANTRONE |
| 220018240 | 220009768 | 1.56 | 78.4 | Curative (C) | 2017-05-01 | 2017-05-15 | Cetuximab 7 day (Cycle 1) | N | N | 220028693 | CARBOPLATIN + IRINOTECAN |
| 220018241 | 220020013 | 1.72 | 68.45 | null | 2018-05-22 | 2018-05-29 | MITOXANTRONE + TRETINOIN | 01 | N | 220028838 | FIGARO TRIAL |
| 220018242 | 220009772 | null | null | Curative (C) | null | 2018-04-19 | Cytarabine+Methotrexate Intrathecal | 02 | null | 220029150 | MITOXANTRONE + TRETINOIN |
| 220018243 | 220009773 | 1.67 | 67.5 | Palliative (P) | 2019-04-12 | 2019-04-13 | Dacarbazine | 02 | null | 220029686 | FLUOROURACIL |
| 220018244 | 220009776 | 1.51 | 47.6 | Curative (C) | 2017-06-26 | 2017-07-18 | Capecitabine | N | N | 220029716 | CAPECITABINE |
| 220018245 | 220015150 | 1.67 | 80 | Curative (C) | 2017-10-30 | 2017-11-08 | DACTINOMYCIN | 2 | N | 220031025 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220018246 | 220021037 | 1.71 | 74 | Curative (C) | null | 2017-09-11 | Cisplatin | N | N | 220031271 | LENALIDOMIDE |
| 220018247 | 220009779 | 1.75 | 64.3 | Palliative (P) | 2017-05-04 | 2017-05-05 | Alemtuzumab + Cyclophos TBI Allo | N | N | 220031497 | DABRAFENIB + TRAMETINIB |
| 220018248 | 220009781 | null | null | null | 2014-08-06 | 2014-08-12 | MACE | N | null | 220031627 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220018249 | 220009782 | 1.36 | 28.5 | null | 2017-06-06 | 2017-10-24 | Carboplatin AUC 6 - 10 | N | Y | 220032124 | MITOXANTRONE + TRETINOIN |
| 220018250 | 220009784 | 1.49 | 62.2 | Curative (C) | 2018-07-10 | 2018-07-30 | Sorafenib | 01 | N | 220032395 | TRABECTEDIN |
| 220018251 | 220009788 | 1.75 | 64.3 | Curative (C) | 2016-05-26 | 2016-07-27 | VINORELBINE | N | N | 220032898 | TOPOTECAN |
| 220018252 | 220018262 | 1.64 | 118.1 | Palliative (P) | 2015-04-21 | 2015-09-13 | BUSULFAN + CYCLO | 2 | N | 220033588 | GEMCITABINE |
| 220018253 | 220021931 | 1.64 | 8.9 | Disease modification (D) | null | 2017-01-29 | ALL UKALL2003 TRIAL | 02 | N | 220033707 | MITOXANTRONE + TRETINOIN |
| 220018254 | 220009791 | 1.53 | 64.1 | Curative (C) | null | 2013-09-15 | Carboplatin AUC 6 - 10 | null | null | 220033759 | FCR |
| 220018255 | 220009792 | 1.68 | 76 | Curative (C) | 2018-05-15 | 2018-06-03 | SPANISH MAINTENANCE | 2 | N | 220034024 | FLA |
| 220018256 | 220009794 | 1.77 | 68 | Curative (C) | 2013-08-02 | 2013-11-08 | MITOXANTRONE + TRETINOIN | N | N | 220034048 | TRASTUZUMAB |
| 220018257 | 220015162 | 1.72 | null | Adjuvant (A) | 2019-01-04 | 2019-06-26 | Sorafenib | null | null | 220034188 | NHL 2003 |
| 220018258 | 220009800 | null | 94.2 | Palliative (P) | 2018-08-13 | 2018-08-16 | Capecitabine + Oxaliplatin 14day | N | N | 220034318 | IPILIMUMAB |
| 220018259 | 220009803 | 1.69 | null | Curative (C) | 2014-08-12 | 2014-08-12 | CYTARABINE + Vosaroxin | N | null | 220034508 | MACE |
| 220018260 | 220009809 | 1.91 | null | Curative (C) | 2018-03-21 | 2018-03-21 | Cytarabine+Methotrexate Intrathecal | null | null | 220034781 | CYCLOPHOSPHAMIDE + ETOPOSIDE HD |
| 220018261 | 220015163 | 1.8 | 68.45 | Curative (C) | null | 2018-08-06 | RAVVA TRIAL | null | N | 220034831 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220018262 | 220009812 | 1.8 | 91.6 | null | 2017-05-24 | 2017-05-24 | BENDAMUSTINE + RITUXIMAB | 2 | Y | 220035216 | CISPLATIN + RT |
| 220018263 | 220009815 | 1.81 | 89.4 | Curative (C) | 2015-05-26 | 2015-07-16 | Cisplatin | 2 | N | 220035338 | LENALIDOMIDE |
| 220018264 | 220015166 | 1.62 | 48 | Disease modification (D) | 2014-10-20 | 2014-10-21 | Carboplatin + Docetaxel | Y | N | 220035346 | CARBOPLATIN + DOCETAXEL |
| 220018265 | 220009818 | 1.44 | null | null | 2012-11-10 | 2013-11-07 | FIGARO TRIAL | N | null | 220035438 | ABVD |
| 220018266 | 220009819 | 1.69 | null | null | null | 2013-08-24 | FIGARO TRIAL | null | null | 220035628 | MYELOMA XI TRIAL |
| 220018267 | 220009822 | 1.7 | 0 | Curative (C) | 2015-03-03 | 2015-03-05 | Mercaptopurine | N | N | 220020987 | MERCAPTOPURINE |